Supply Chain Intelligence

Gilead Sciences, Inc. Supply Chain

GILD supply chain intelligence for Gilead Sciences, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

GILD ·Last updated 2026-07-29 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

21Suppliers
27Customers
2Debt Items
20Related Chains

Gilead Sciences, Inc. Suppliers

TickerNameConfidenceEvidence
IOCB IOCB 90% License Agreement, dated December 15, 1991, between Registrant, IOCB and REGA
REGA REGA 90% License Agreement, dated December 15, 1991, between Registrant, IOCB and REGA
CGEN Compugen Ltd. 85% Reciprocal relationship from CGEN graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CGEN graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CGEN g…
EMORY-UNIVERSITY EMORY-UNIVERSITY 85% Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,…
GLAXO-GROUP-LIMITED GLAXO-GROUP-LIMITED 85% Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,…
GLAXO-WELLCOME-INC GLAXO-WELLCOME-INC 85% Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,…
THE-WELLCOME-FOUNDATION-LIMITED THE-WELLCOME-FOUNDATION-LIMITED 85% Exclusive License Agreement by and between Registrant (as successor to Triangle Pharmaceuticals, Inc.), Glaxo Group Limited, The Wellcome Foundation Limited, Glaxo Wellcome Inc. and Emory University,…
CAH Cardinal Health, Inc. 72% Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var…
CAH Cardinal Health, Inc. 72% erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We…
CHRS Coherus Oncology, Inc. 72% Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors), servicing account specific questions regarding the billing, coding and reimburs…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC graph: Reciprocal relationship from GILD graph: Reciprocal relationship from GDTC g…
GLAXF GSK plc 72% Reciprocal relationship from GLAXF graph: rporate and other unallocated impairment reversals ( 3 ) ( 14 ) – Other reconciling items between segment impairment reversals and total impairment reversals…
IBIO iBio, Inc. 72% Reciprocal relationship from IBIO graph: icantly more experience commercializing drugs that have been approved for marketing. Mergers and acquisitions in the pharmaceutical and biotechnology industri…
KYTX Kyverna Therapeutics, Inc. 72% Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: ase 1 data from both of these trials in the second half of 2025. In November…
MCK McKesson Corporation 72% Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var…
MCK McKesson Corporation 72% erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We…
MGNX MacroGenics, Inc. 72% Reciprocal relationship from MGNX graph: perations. Recent tax reforms in the United States have resulted in significant changes to preexisting U.S. tax rules and regulations. These changes may trigg…
NRIX Nurix Therapeutics, Inc. 72% Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: g Administration (FDA), the European Medicines Agency (EMA) or other regulat…
PYXS Pyxis Oncology, Inc. 72% Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS g…
RCUS Arcus Biosciences, Inc. 72% Reciprocal relationship from RCUS graph: hase Agreement Amendment; and $ million deferred revenue remaining from the First Gilead Collaboration Agreement Amendment effective December 2021. We determi…
XNCR Xencor, Inc. 72% Reciprocal relationship from XNCR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from XNCR graph: these consolidated financial statements. 77 Xencor, Inc. Notes to Consolidat…

Gilead Sciences, Inc. Customers

TickerNameConfidenceEvidence
CAH Cardinal Health, Inc. 85% erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We…
CAH Cardinal Health, Inc. 85% Reciprocal relationship from CAH graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var…
CARDINAL-HEALTH-INC-CENCORA-INC CARDINAL-HEALTH-INC-CENCORA-INC 85% atterns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe.…
MCK McKesson Corporation 85% erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed variations in purchasing patterns induced by cost containment measures in Europe. We…
MCK McKesson Corporation 85% Reciprocal relationship from MCK graph: Reciprocal relationship from GILD graph: erns of our non-retail customers. In light of the budget crises faced by many European countries, we have observed var…
BMY Bristol-Myers Squibb Company 72% O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma …
BMY Bristol-Myers Squibb Company 72% Reciprocal relationship from BMY graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement…
BMYMP Bristol-Myers Squibb Co 72% Reciprocal relationship from BMYMP graph: Reciprocal relationship from GILD graph: Reciprocal relationship from BMYMP graph: Reciprocal relationship from GILD graph: O Pharma will hold exclusive glob…
BMYMP Bristol-Myers Squibb Co 72% O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma …
CHRS Coherus Oncology, Inc. 72% Reciprocal relationship from CHRS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from CHRS graph: plans and pension benefit managers (via a team of National Account Directors…
GDTC CytoMed Therapeutics Limited 72% Reciprocal relationship from GDTC graph: l expansion. ATPL retained the right to use all products and/or services the Company creates which contain or incorporate the modified human K562 cells. Any n…
GLSI Greenwich LifeSciences, Inc. 72% Reciprocal relationship from GLSI graph: duct candidate and the average exposure time in the clinical development program may be inadequate to detect rare adverse events or chance findings that may o…
IDYA IDEAYA Biosciences, Inc. 72% Reciprocal relationship from IDYA graph: sertib (PKC) Phase 2/3 clinical trials, IDE397 (MAT2A) Phase 1/2 clinical trials, IDE849 (DLL3) Phase 1 clinical trial, IDE161 (PARG) Phase 1/2 clinical trial…
INTS Intensity Therapeutics, Inc. 72% Reciprocal relationship from INTS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from INTS graph: n when they do not submit claims directly to government payors if they are d…
JNJ Johnson & Johnson 72% Reciprocal relationship from JNJ graph: Reciprocal relationship from GILD graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from GILD graph: Reciprocal relationship from JNJ grap…
JNJ Johnson & Johnson 72% O Pharma will hold exclusive global rights to STAT6 topical formulations in dermatology. Upon closing of the agreement, we made a $ 250 million upfront payment to LEO Pharma. In addition, LEO Pharma …
KYMR Kymera Therapeutics, Inc. 72% Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYMR g…
KYTX Kyverna Therapeutics, Inc. 72% Reciprocal relationship from KYTX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from KYTX graph: . The Company recognized $ million and in impairment charges related to capi…
LQDA Liquidia Corporation 72% Reciprocal relationship from LQDA graph: perational fabrication lines are scaled and capable of producing the necessary materials to support our clinical trials and, if approved, initial commercial d…
MGNX MacroGenics, Inc. 72% Reciprocal relationship from MGNX graph: lations, which include requirements relating to quality control and quality assurance as well as the corresponding maintenance of records and documentation. F…
NRIX Nurix Therapeutics, Inc. 72% Reciprocal relationship from NRIX graph: Reciprocal relationship from GILD graph: Reciprocal relationship from NRIX graph: g Administration (FDA), the European Medicines Agency (EMA) or other regulat…
PYXS Pyxis Oncology, Inc. 72% Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitab…
RNTX Rein Therapeutics Inc. 72% Reciprocal relationship from RNTX graph: development stage. Manufacturing We do not own or operate manufacturing facilities for the production of any of our product candidates, nor do we have plans t…
CYMABAY-THERAPEUTICS-INC CYMABAY-THERAPEUTICS-INC 62% erivatives designated as hedges: Net gain (loss) recognized in Accumulated other comprehensive income $ 171 $ ( 14 ) $ 150 Net gain reclassified from Accumulated other comprehensive income into Produ…
JAPAN-TOBACCO-INC JAPAN-TOBACCO-INC 62% on agreement with Janssen to develop and commercialize a fixed-dose combination of Janssen’s darunavir and our cobicistat, emtricitabine and tenofovir alafenamide (“Gilead Compounds”). This combinati…
MIROBIO-LTD MIROBIO-LTD 62% purchase price related to various other assets acquired and liabilities assumed, consisting primarily of deferred tax assets. Under the agreement, the former shareholders of Tmunity and the Universit…
TMUNITY-THERAPEUTICS-INC TMUNITY-THERAPEUTICS-INC 62% 48 434 238 116 47 401 8 % Total HIV 15,918 2,339 1,355 19,612 14,848 2,102 1,226 18,175 8 % Liver Disease Sofosbuvir/Velpatasvir (3) 922 299 374 1,596 859 323 355 1,537 4 % Vemlidy 486 44 428 959 410…

Gilead Sciences, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
GILD-DEBT Debt stack $22.2B 90% Market cache reports total debt of $22.2B.
GILD-DEBT-7255 Xbrl Convertible 90% xbrl convertible detail from xbrl 2011-12-31.

Gilead Sciences, Inc. Acquisitions

Acquired EntityNameConfidenceEvidence
GILD-ACQ-0001104659-26-049874 Gilead completed the acquisition of Arcellx, Inc. through a tender offer and merger. 85% Gilead completed the acquisition of Arcellx, Inc. through a tender offer and merger.

Gilead Sciences, Inc. Ownership

HolderNameConfidenceEvidence
GILD-OWNER-GILEAD-SCIENCES-INC GILEAD SCIENCES, INC. 90% 13F overlay lists GILEAD SCIENCES, INC. as top holder; 209 tracked holders.

Gilead Sciences, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
RXRX Recursion Pharmaceuticals, Inc. 100.00 2
CCCC C4 Therapeutics, Inc. 100.00 2
WHWK Whitehawk Therapeutics, Inc. 100.00 2
BEAM Beam Therapeutics Inc. 100.00 2
BORAY Bora Pharmaceuticals Co., Ltd. 100.00 2
BNRG Brenmiller Energy Ltd 100.00 2
CVS CVS Health Corporation 100.00 2
BPTH Bio-Path Holdings, Inc. 100.00 2
BLLN BillionToOne, Inc. 100.00 2
ANIK Anika Therapeutics, Inc. 100.00 2
ANL Adlai Nortye Ltd. 100.00 2
CLYM Climb Bio, Inc. 100.00 2
BNR Burning Rock Biotech Limited 100.00 2
AORT Artivion, Inc. 100.00 2
AVBP ArriVent BioPharma, Inc. 100.00 2
FATE Fate Therapeutics, Inc. 100.00 2
EMMA Emmaus Life Sciences, Inc. 100.00 2
CYTOF Altamira Therapeutics Ltd. 100.00 2
CTMX CytomX Therapeutics, Inc. 100.00 2
AZN AstraZeneca PLC 100.00 2
View GILD supply chain intel →

Explore the full interactive supply chain map for Gilead Sciences, Inc..

Open GILD supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map